Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Videos
SABCS 2017
SABCS 2017
The Mechanism of Action of CDK4/6 Inhibitors
FEATURING:
Matthew P. Goetz, MD
Breast Cancer
,
SABCS 2017
Watch Video
The Use of Chemotherapy in the Metastatic Setting
FEATURING:
Matthew P. Goetz, MD
SABCS 2017
,
Breast Cancer
,
SABCS 2017
Watch Video
Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
FEATURING:
Matthew P. Goetz, MD
Breast Cancer
,
SABCS 2017
,
SABCS 2017
Watch Video
Questions About Treating Patients Using a CDK4/6 Inhibitor
FEATURING:
Matthew P. Goetz, MD
SABCS 2017
Watch Video
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
FEATURING:
Matthew P. Goetz, MD
Breast Cancer
,
SABCS 2017
Watch Video
Hot Topics at SABCS 2017
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
HER2-Positive Breast Cancer and CDK4/6 Inhibitors
FEATURING:
Hope S. Rugo, MD
Breast Cancer
,
SABCS 2017
Watch Video
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
2023 Spotlight: Amgen
3.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes